Form 4 for CNSP CNS Pharmaceuticals, Inc.
Accepted 2024-02-06 00:00:00 ET · period of report 2024-02-01 · accession 0001683168-24-000708 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-02-06 | 2024-02-01 | CNSP | Gumulka Jerzy | Dir | P - Purchase | $0.3 | +33.3K | 43.0K | +345% | +$10,000 |
| DM | 2024-02-06 | 2024-02-01 | CNSP | Gumulka Jerzy | Dir | A - Grant | — | +66.7K | 112.1K | +147% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common stock | 2024-02-01 | P | A | 33,333 | $0.3 | 43,006 | D | — | — | (F1) The common stock, Series A warrants and Series B warrants were acquired by the reporting person in a public offering conducted by the Company that was closed on February 1, 2024. |
| 2 | Derivative | Series A Warrant to purchase common stock | 2024-02-01 | A | A | 33,333 | — | 78,761 | D | $0.3 · 2024-02-01 to 2029-02-01 | 33,333 Common Stock | (F1) The common stock, Series A warrants and Series B warrants were acquired by the reporting person in a public offering conducted by the Company that was closed on February 1, 2024. |
| 3 | Derivative | Series B Warrant to purchase common stock | 2024-02-01 | A | A | 33,333 | — | 112,094 | D | $0.3 · 2024-02-01 to 2025-10-01 | 33,333 Common Stock | (F1) The common stock, Series A warrants and Series B warrants were acquired by the reporting person in a public offering conducted by the Company that was closed on February 1, 2024. |